Hedge Fund - Bridger Management

In a newly-amended 13D filing, Roberto Mignone's Bridger Management reported holding 3.29 million shares of TrovaGene Inc (NASDAQ:TROV) which represent 11% of the company’s outstanding stock.

The hedge fund industry as a whole did not perform particularly well in 2015, but there were a few investment vehicles that managed to greatly outperform the broader market.

According to a 13G filing with the Securities and Exchange Commission, Roberto Mignone's Bridger Management currently owns 6.4% of Chimerix Inc (NASDAQ:CMRX).

Is it a good time to buy Kite Pharma Inc (NASDAQ:KITE)? Andreas Halvorsen seems to think so, having recently increased his holding of the stock.

Bridger Management, led by Roberto Mignone, has filed its 13F with the SEC for the current reporting period. Bridger Management is a New York-based hedge fund which was founded in July 2000.

According to two recent filings with the Securities and Exchange Commission, Kevin Kotler's (pictured) Broadfin Capital and Roberto Mignone's Bridger Management have disclosed stakes amounting to 900,...

Roberto Mignone’s Bridger Management has acquired more shares of TrovaGene Inc. (NASDAQ:TROV).

Roberto Mignone's Bridger Management is a fund with around $2.0 billion in assets, one that is focused on healthcare stocks, which represent nearly one-half of the fund's equity portfolio.

Roberto Mignone’s Bridger Management has amassed a 5.5% stake in Arrowhead Research Corp (NASDAQ:ARWR) according to a 13G filing with the Securities and Exchange Commission on January 23.